Daily Stock Analysis, BLPH, Bellerophon Therapeutics Inc, priceseries

Bellerophon Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
2.22
Close
2.22
High
2.22
Low
2.15
Previous Close
2.20
Daily Price Gain
0.02
YTD High
2.71
YTD High Date
Jan 4, 2018
YTD Low
1.86
YTD Low Date
Feb 9, 2018
YTD Price Change
-0.31
YTD Gain
-12.25%
52 Week High
2.74
52 Week High Date
Dec 18, 2017
52 Week Low
0.90
52 Week Low Date
Feb 17, 2017
52 Week Price Change
1.14
52 Week Gain
105.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 22. 2017
1.54
Dec 5. 2017
1.86
8 Trading Days
20.73%
Link
LONG
Dec 11. 2017
2.09
Dec 19. 2017
2.22
6 Trading Days
6.34%
Link
Company Information
Stock Symbol
BLPH
Exchange
NasdaqGM
Company URL
http://www.bellerophon.com
Company Phone
908-574-4770
CEO
Fabian Tenenbaum
Headquarters
New Jersey
Business Address
184 LIBERTY CORNER ROAD, SUITE 302, WARREN, NJ 07059
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001600132
About

Bellerophon Therapeutics, Inc. engages in developing products at the intersection of drugs and devices. Its products are using in the treatment of cardiopulmonary and cardiac diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

Description

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates is INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.